Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status

Journal of Clinical Oncology

Volumn 20, Issue 3, 2002, Pages 850-856

  Costa, Luis ^a   Demers, Laurence M ^a   Gouveia Oliveira, A ^a   Schaller, J ^a   Costa, Eduardo B ^a   De Moura, Miguel C ^a   Lipton, Allan ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE NEOPLASMS; COLLAGEN; COLLAGEN TYPE I; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PEPTIDES; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0036468002     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.3.850     Document Type: Article

References (18)

1. The anatomy and pathways of skeletal metastases
2. The clinical course of bone metastases from breast cancer
3. Biochemical markers of bone turnover in patients with metastatic bone disease
4. Biochemical markers and skeletal metastases
5. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy
6. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
7. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
8. Markers of bone resorption in breast cancer-induced osteolysis before and after bisphosphonates
9. Monitoring of multiple myeloma patients by simultaneously measuring markers substances of bone resorption and formation
10. The palliation of symptomatic osseous metastases: Final results of the study by the Radiation Therapy Oncology Group
11. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer
12. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease
13. Markers of bone resorption in patients treated with pamidronate
14. Assessment of bone response to systemic therapy in a EORTC trial: Preliminary experience with the use of collagen cross-link excretion
15. Measurement of urinary collagen cross-links indicate response to therapy inpatients with breast cancer and bone metastases
16. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer
17. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma
18. Type I and type III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer